Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure: baseline characteristics of patients in the RESHAPE-HF2 trial

13 May 2024 (09:18 - 09:26)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Professor Stefan Anker

Charite University Hospital, Berlin (Germany)

9 More presentations in this session

Presentation thumbnail

Effect of IV iron in patients with heart failure with preserved ejection fraction

Professor S. von Haehling (Goettingen, DE)

Presentation thumbnail

Discussant review - FAIR-HFpEF

Professor P. Kalra (Portsmouth, GB)

Presentation thumbnail

Semaglutide 2.4 mg and NTproBNP in obesity-related HFpEF: insights from the STEP-HFpEF programme

Professor M. Petrie (Glasgow, GB)

Presentation thumbnail

Discussant review - STEP HFpEF Program

Professor A. Bayes Genis (Badalona, ES)

Presentation thumbnail

Design and baseline characteristics of REALIZE K: a placebo-controlled randomized-withdrawal trial of sodium zirconium cyclosilicate for hyperkalaemia management in patients with HF and reduced EF

Doctor M. Kosiborod (Kansas City, US)

Access the full session

Session thumbnail

Late breaking clinical trials: further analyses and baseline characteristics

The Event

Event poster

Heart Failure 2024

13 May 2024 09:18 CET

You may be interested in

Congress Presentation

Discussant review - RESHAPE-HF2

Congress Presentation

RESHAPE-HF2 - Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure

Congress Presentation

Device treatment of secondary mitral regurgitation

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources